Cell and Gene Therapy Manufacturing Exposes the Cost of Delayed Digital Infrastructure

Cell and Gene Therapy Manufacturing Exposes the Cost of Delayed Digital Infrastructure

ERP Today
ERP TodayMar 27, 2026

Why It Matters

Without a unified digital infrastructure, CGT programs cannot reliably scale, exposing them to regulatory penalties and eroding investor confidence.

Key Takeaways

  • Manual handoffs hinder CGT scalability
  • Digital orchestration ensures traceability and auditability
  • Early automation cuts cycle time up to 62%
  • Integrated platforms attract investors and regulators

Pulse Analysis

The rapid maturation of cell and gene therapies has shifted the bottleneck from scientific discovery to manufacturing execution. While laboratories can adopt rigorous protocols, the surrounding logistics—sample collection, cryogenic transport, processing, and release—often rely on spreadsheets and email threads. This fragmented approach amplifies error risk, especially as each batch represents a single patient, and it hampers the ability to meet tight regulatory expectations for chain‑of‑identity and data integrity.

Digital orchestration platforms, such as SAP’s CGT Orchestration, address these challenges by providing a single source of truth across all stakeholders. Features like automated e‑signatures, dual patient identifier checks, scan‑to‑verify custody transfers, and real‑time integration with third‑party logistics create proactive alerts for temperature excursions or shipment delays. By capturing data contemporaneously and structuring it for audit, companies can demonstrate compliance during early‑phase inspections, turning a perceived efficiency tool into a regulatory safeguard.

Strategically, early investment in a modular, cloud‑based orchestration layer signals operational maturity to investors and partners. It reduces rework, shortens cycle times, and preserves institutional knowledge as programs scale from a handful of patients to dozens. As CGT pipelines expand, firms with integrated digital backbones will achieve sustainable margins, faster market entry, and stronger negotiating positions with payers and regulators, making digital readiness a decisive competitive advantage.

Cell and Gene Therapy Manufacturing Exposes the Cost of Delayed Digital Infrastructure

Comments

Want to join the conversation?

Loading comments...